Weize Huang

7PUBLICATIONS
25CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Pharmaceutical delivery technologiesMolecular targetsPharmacogenomicsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 02, 2026
Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial.

Jeff P Sharman, Luca Laurenti, Emmanuelle Ferrant

|Nov 06, 2025
Utilizing Minimal Physiologically Based Pharmacokinetic Modeling to Bridge Bevacizumab Pharmacokinetics from Adult to Pediatric Patients.

Olagoke Sule, Felix Stader, Nastya Kassir

|Jul 29, 2024
A Comparative Clinical Pharmacology Analysis of FDA-Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology.

Huy X Ngo, Yue Winnie Wen, Swathi Pisupati

|Nov 03, 2023
Predicting complex kidney drug handling using a physiologically-based pharmacokinetic model informed by biomarker-estimated secretory clearance and blood flow.

Michael L Granda, Weize Huang, Catherine K Yeung

|Oct 20, 2022
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.

Naval G Daver, Monique Dail, Jacqueline S Garcia

|Sep 25, 2020
Novel Mechanistic PBPK Model to Predict Renal Clearance in Varying Stages of CKD by Incorporating Tubular Adaptation and Dynamic Passive Reabsorption.

Weize Huang, Nina Isoherranen

Pageof 2

Frequent Collaborators

2 joint publications

Nina Isoherranen

1 joint publications

Lindsay C Czuba

1 joint publications

Naval G Daver

1 joint publications

Jacqueline S Garcia